LinkedIn founder Reid Hoffman and Siddhartha Mukherjee, cancer researcher and author of the book “The Emperor of All Maladies,” have co-founded an

The LinkedIn founder talks about his new book, ‘Superagency,’ and argues that people can use AI to reshape their daily work lives.

What Could Possibly Go Right with Our AI Future," the LinkedIn co-founder makes the case that AI can extend human

Hoffman isn’t the only prominent Silicon Valley figure betting on A.I.’s promise in medical research. The new technology is expected to generate between $60 billion and $110 billion annually in value for the pharmaceutical and medical-product industries, according to a McKinsey report released last year.

Manas AI Inc., a startup using artificial intelligence to discover new medicines, launched today with $24.6 million in initial funding. The investment was led by General Catalyst and Manas AI co-founder Reid Hoffman. Greylock Partners, where Hoffman was a general partner until 2023, participated as well.

Dedicated to spotlighting global leaders, the Tarnopol series serves as a platform for addressing critical societal issues, including AI’s potential and ethical implications.

LinkedIn co-founder and AI investor Reid Hoffman argues we shouldn't be afraid of AI or its disruptive capabilities in his new book "Superagency: What Could Possibly Go Right with Our AI Future."

Better to share technology broadly, in bite-size increments, than to smother it with regulation from the start, prompted by our worst fears.

The LinkedIn co-founder is starting Manas AI with “The Emperor of All Maladies” author Siddhartha Mukherjee.

The early investor in OpenAI tells VF that Big Tech’s proximity to Donald Trump is “really important” and argues that DeepSeek’s breakthrough in China demonstrates how “strong the competitive talent” is that America faces.

The author of the seminal cancer biography The Emperor Of All Maladies and the co-founder of LinkedIn are looking to connect their skills to the development of new medicines by launching a new artificial intelligence-driven drug discovery outfit.